Relative differences (mean ± standard deviation) in gene expression of <i>GDF-15</i>, <i>ATF3</i>, <i>AREG</i> in HMEC-1 after “acute” exposure to bleomycin and cisplatin measured by qRT-PCR.

<p>Relative differences (mean ± standard deviation) in gene expression of <i>GDF-15</i>, <i>ATF3</i>, <i>AREG</i> in HMEC-1 after “acute” exposure to bleomycin and cisplatin measured by qRT-PCR.</p

Top 50 genes with largest difference in expression in the different exposition settings in HMEC-1.

<p>* Overlapping genes in the “acute” exposure setting for both drugs,</p><p>^† Overlapping genes in the “chronic” exposure setting for both drugs.</p><p>^‡ Overlapping genes in the “acute” and “chronic” exposure setting for bleomycin.</p><p>^§ Overlapping genes in the “acute” and “chronic” exposure setting for cisplatin.</p><p>Top 50 genes with largest difference in expression in the different exposition settings in HMEC-1.</p

Gene Set Enrichment Analysis on gene expression profiles from HMEC-1 following “acute” and “chronic” exposure to bleomycin and cisplatin, using pathway definitions from KEGG.

<p>No pathways were enriched according to these criteria after “chronic” exposure to bleomycin.</p><p>Gene Set Enrichment Analysis on gene expression profiles from HMEC-1 following “acute” and “chronic” exposure to bleomycin and cisplatin, using pathway definitions from KEGG.</p

Plasma levels of GDF-15 (pg/mL), vWF (%) and hsCRP (mg/L) in testicular cancer patients (n = 41) before, during and after completion of bleomycin- and cisplatin-based chemotherapy.

<p>* <i>P</i> < 0.01 compared to baseline, Wilcoxon signed rank test</p><p>^†<i>P</i> < 0.05 compared to baseline, Wilcoxon signed rank test</p><p>^‡<i>P</i> < 0.01 compared to one month after completion of chemotherapy, Wilcoxon signed rank test</p><p>^§<i>P</i> < 0.05 compared to one month after completion of chemotherapy, Wilcoxon signed rank test</p><p>Plasma levels of GDF-15 (pg/mL), vWF (%) and hsCRP (mg/L) in testicular cancer patients (n = 41) before, during and after completion of bleomycin- and cisplatin-based chemotherapy.</p

Characteristics of 41 patients with disseminated testicular cancer and treated with cisplatin containing combination chemotherapy.

<p>Abbreviations: International Germ Cell Cancer Collaborative Group (IGCCCG); bleomycin etoposide cisplatin chemotherapy (BEP).</p><p>Characteristics of 41 patients with disseminated testicular cancer and treated with cisplatin containing combination chemotherapy.</p

Supplementary Figure 4 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTORC1/2 downstream pathway evaluation in Tera cells</p

Patient characteristics and lesion distribution.

<p>Patient characteristics and lesion distribution.</p

Supplementary Figure 2 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Dasatinib in combination with cisplatin in resistant TC cells</p

Supplementary Figure 3 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTOR knock down in combination with cisplatin in resistant TC cells</p

Distribution of retroperitoneal lymph nodes.

<p>RPAO: right para-aortic, LPAO: left para-aortic, CLRV: caudal left renal vein, CAV: vena cava, AOB: aortic bifurcation.</p